Sitemap - 2024 - The Microdose

Finding psychedelic prior art: 5 Questions for Porta Sophia’s Shahin Shams

Will Colorado cities pass psilocybin restrictions? DEA begins hearings on scheduling psychedelic research drugs; New study finds hallucinogen-related ER visits associated with increased risk of future

Rerun: 5 Questions for Zach Skiles

What will a Trump Administration do with psychedelics?; Massachusetts voters reject Question 4; and Oregon municipalities appear to opt-out of psilocybin services

Will Massachusetts vote for psychedelics? 5 Questions for Boston-based reporter Jack Gorsline

Compass Pathways announced study delays, layoffs; Dispatch from Boston: Advocates rally in support of Question 4

The illusory trip: 5 Questions for psychologist and magician Jay Olson

How much MDMA is in your “MDMA”?; Judge largely denies DEA’s bid to dismiss testimony in upcoming DOI/DOC hearing; and sexual misconduct and adverse experiences in the underground

A Navy SEAL Goes to Mexico to take Ibogaine

Head movies and acid westerns: 5 Questions for film historian and archivist Haden Guest

Massachusetts psychedelics ballot measure race heats up; Psychedelic study designs affect the magnitude of antidepressant effects; Is New Jersey next?

The Peyote Plan

Why are we doing this? 5 Questions for doctor and MDMA researcher Sylver Quevedo

DEA seeks to exclude testimony and evidence in case of two drugs used in psychedelic research; The role of therapy in psychedelic therapy; and Portlanders introduce Psychedelic Health Act

What if Ketamine is More Addictive Than We Thought?

Psychedelic, empathogen, connectogen — how do we classify MDMA? 5 Questions for neuroscientist Matt Baggott

Psilocybin and SSRIs perform similarly six months after treatment; Oregon psilocybin program proposes revised rules; DEA increases quotas for psilocybin and psilocin

Psychedelics on the Ballot

Ketamine’s abuse potential: 5 Questions for psychiatrist Jennifer Swainson

A Former War Correspondent Unravels

Autism, dogs and LSD; Review paper says certainty of evidence for psychedelic-assisted therapy is “low to very low;” and millions could be eligible for psilocybin-assisted therapy

Vikings, Super Mario Brothers, Santa and Gummies: 5 Questions for Amanita muscaria expert Kevin Feeney

Psychedelics and the social cure; Industry shake-ups; Tracking adverse events

Dueting with the universe: 5 Questions for musician Jon Hopkins

Standardizing the measurement of psychedelic side effects; Doctor charged in Matthew Perry’s death pleads guilty; and predicting a trip’s outcome

Ibogaine & Basketball

High-dose psilocybin more effective than antidepressant according to meta-analysis; DEA hearing on two obscure drugs; DEA administrator speaks out against illegal ketamine prescribing

The Longest Trip

The Peace Seekers

A new kind of psychedelic art: 5 Questions for Elastic Magazine founder Hillary Brenhouse

Massive Lykos and MAPS layoffs amid FDA rejection reactions; Three MDMA papers retracted; and false insights

“The age of psychedelic inequity”: 5 Questions for author Alissa Quart

Breaking News: Federal regulators reject MDMA-assisted therapy for PTSD

Altered States listen to episodes 1 & 2

What happens when an anthropologist embeds in a psychedelic clinical trial?: 5 Questions for researcher Amadeus Harte

Colorado municipalities consider opting out of psilocybin services; Is MDMA an empathogen, an entactogen, or connectogen?; and recent brain imaging results made a splash, but what do they mean?

How are people using psychedelics out in the world?: 5 Questions for Unlimited Sciences researcher Matthew X. Lowe

Ibogaine company receives $15 million from Google co-founder’s nonprofit; Could a road through federal land derail a planned psilocybin center in Oregon?; questions remain about FDA’s investigation

Psychedelics for dogs?: 5 Questions for veterinarian Carlo Siracusa

Your brain on psilocybin; Massachusetts to vote on psychedelic ballot initiative in November; and two new species of Psilocybe mushrooms discovered

Kentucky’s Ibogaine Evangelist

Should neuroscience researchers embrace religion and spirituality? Washington psychedelics ballot initiative advances; and learning from pre-1970s psychedelics researchers

Psychedelic science comics: 5 Questions for artist and cartoonist Audra McNamee

RAND Corporation report digs into U.S. psychedelic use; Yet another California psychedelics bill dies; The latest on Lykos and MDMA-assisted therapy

Prescriptions for MDMA and psilocybin in Utah?: 5 Questions for Republican State Senator Kirk A. Cullimore

Government report recommends that the DEA increase transparency for psychedelic churches, and largest study yet of at-home ketamine effects

Acid blotter paper art: 5 Questions for author Erik Davis

The psychedelics world reacts after a FDA Advisory Committee votes against MDMA for PTSD

Psychedelic Outlaws

Breaking News: F.D.A. Panel Votes Against MDMA-Assisted Therapy for PTSD

MDMA's next step towards FDA approval: 5 Questions for FDA advisory committee member Suzanne Robotti

Public comments on upcoming FDA Advisory Committee; ICER council votes evidence for MDMA-assisted therapy is inadequate; and disentangling psychedelics and therapy

Ayahuasca church & owner to pay $15 million in wrongful death suit; State bills updates in VT, MD, IL, & NY; and the risks and benefits of integration groups

Conflicts of interest: 5 Questions for researcher Elena Koning

Revisions made to report critical of Lykos’s research on MDMA-assisted therapy; Lawsuit postpones hearing for contentious DEA proposal; and former MAPS employees make troubling allegations

Drug recriminalization in Oregon: 5 Questions for attorney Jon Dennis

U.S. Food & Drug Administration will hold advisory committee meeting on MDMA; A psychedelics research bottleneck in California; and psilocybin meta-analysis under post-publication review

What do we know about the psychedelic underground?: 5 Questions for drugs researcher Crystal Lederhos Smith

Preparing insurers and patients for MDMA-assisted therapy; NIH announces $20 million grant to study psychedelics and chronic pain; Are psychedelics an “inner healer”?

Psychedelics 101 for doctors: 5 Questions for Psychedelic Medicine Association founder Lynn Marie Morski

Federal agencies settle with ayahuasca church; U.S. reps urge VA to prepare for MDMA approval; CO bill could hamper psychedelics discussion on social media

Hasidic Judaism and Psychedelics: 5 Questions for Jewish studies scholar Sam Shonkoff

No serious adverse reactions recorded in synthetic 5-MeO-DMT study; California psychedelics bill advances; Are medical trainees ready for psychedelics?

Is it okay to give psychedelics to someone in a vegetative state?: 5 Questions for journalist Jonathan Moens

DEA announces hearing on obscure hallucinogenic compounds; Petitioning the FDA for a public meeting on Lykos and MDMA; Psychedelic church sues for defamation

Measuring the ineffable: 5 Questions for mystical experience researcher Kurt Stocker

Indigenous ketamine therapy: 5 Questions for First Nations mental health leader Emmy Manson

Tapering off antidepressants before psilocybin treatment; New concerns about MAPS’s MDMA trials; University of Maryland Baltimore joins patent lawsuit against Compass

Cognitive impairment, dementia, Alzheimer’s and psychedelics: 5 Questions for researcher Albert Garcia-Romeu

Another Breakthrough Therapy Designation for a psychedelic drug from the FDA; A critique of the mixing of psychedelic science and spirituality at Johns Hopkins; The patient-therapist bond

Cops for psychedelic reform: 5 Questions for retired police officer Dave Franco

“Hey, whatever happened to the tapes you made when I was high?”

MindMed receives FDA breakthrough therapy designation for LSD; Psychedelics figure Ben Sessa’s medical license suspended for one year; Serotonin toxicity after combining psilocybin and antidepressants

What is happening in Europe?: 5 Questions for Psychedelic Access and Research European Alliance founder Tadeusz Hawrot

Psilocybin-related calls to poison control centers increasing; former Kentucky ibogaine advocate to continue his work in Ohio; Colorado issues draft psilocybin rules

What happens when MDMA is approved as a prescription drug? 5 Questions for regulatory attorney Kimberly I. Chew

Psychedelic preparation going digital, more Canadian raids, and a new psilocybin services bill in Arizona

FDA will fast-track Lykos’s application for MDMA-assisted therapy for PTSD; New Illinois bill; and Canada’s first psilocybin clinical trial

Palliative care and psychedelics: 5 Questions for physician Rachel Rackow

Law enforcement seizures of psychedelic mushrooms skyrocket; Could psychedelics lead to better sex? And will CA be the next state to launch a psychedelics program?

What can Colorado learn from Oregon about psilocybin?: 5 Questions for Healing Advocacy Fund’s Colorado director Tasia Poinsatte

A cornucopia of new bills; Canadians support end-of-life psilocybin therapy; and tempering the hype

An undergrad, twitching rodent heads, DOI, and the DEA: 5 Questions for researcher Alyssa Gillies

Probing expectancy effects; EU to spend big on psilocybin trial; MDMA-assisted therapy may improve self-compassion

“Stop using wild San Pedro”: 5 Questions for Josip Orlovac Del Río

The long history of Psilocybe’s evolution; New bills in Indiana, California, and New Jersey; and COMPASS partners with a healthcare non-profit

Should Kentucky spend $42 million on ibogaine research? 5 Questions for drug abuse researcher William Stoops

Could ibogaine help treat brain injuries? MAPS rebrands its for-profit company; New year, new bills in AZ and RI

Drug use at the nightclub: 5 questions for drug epidemiologist Joseph Palamar

Kentucky ibogaine proposal in flux; A look at year one of psilocybin services in Oregon; Drug Enforcement Administration proposes to restrict two new drugs